Clinical Global Impression ‐ Change (CGI‐C), proportion much improved or very much improved at week 3 № of participants: 70 (1 RCT) · idiopathic hypersomnia
Modafinil probably leads to higher clinical Global Impression ‐ Change (CGI‐C), proportion much… compared with placebo (moderate certainty).
1 finding from 1 review
OR 5.14 [1.76, 15]
Studies not reported
Moderate
improvement in the maintenance of wakefulness test · idiopathic hypersomnia
1 finding from 1 review
no estimate extracted
Studies not reported
High
Effectiveness · idiopathic hypersomnia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Number of participants with any adverse events№ of participants: 102(2 RCTs) · idiopathic hypersomnia
Modafinil showed no clear difference in number of participants with any adverse events№ of participants:… compared with placebo (low certainty).
1 finding from 1 review
OR 1.68 [0.28, 9.94]
Studies not reported
Low
Daytime sleepiness (ESS): change from baseline. · idiopathic hypersomnia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Sleepiness · idiopathic hypersomnia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Relapse at 3 months · SSNS in children
Rituximab probably leads to lower relapses at 3 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Frequent relapses · SSNS in children
Mycophenolate mofetil showed no clear difference in frequent relapses at 12 months compared with levamisole (low certainty).
1 finding from 1 review
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Peritonitis · SSNS in children
It is very uncertain whether mycophenolate mofetil changes adverse effects: peritonitis compared with levamisole (very low certainty).
1 finding from 1 review
Abdominal pain · SSNS in children
Mycophenolate mofetil showed no clear difference in adverse effects: abdominal pain compared with levamisole (low certainty).
1 finding from 1 review
Adverse effects: anaemia · SSNS in children
It is very uncertain whether mycophenolate mofetil changes adverse effects: anaemia compared with levamisole (very low certainty).
1 finding from 1 review
Adverse effects: leukopenia · SSNS in children
It is very uncertain whether mycophenolate mofetil changes adverse effects: leukopenia compared with levamisole (very low certainty).
1 finding from 1 review
Relapse · SSNS in children
Mycophenolate mofetil showed no clear difference in relapse at 12 months compared with cyclosporin (low certainty).
1 finding from 1 review
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Annualised relapse rate · SSNS in children
1 finding from 1 review
Adverse events: hypertension · SSNS in children
Mycophenolate mofetil showed no clear difference in adverse effects: hypertension compared with cyclosporin (low certainty).
1 finding from 1 review
Relapse · SSNS in children
Rituximab probably leads to lower relapses at 6 months compared with placebo or control (moderate certainty).
2 findings from 1 review
Adverse effects: hypertrichosis · SSNS in children
Mycophenolate mofetil may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).
1 finding from 1 review
Adverse effects: lymphopenia · SSNS in children
Mycophenolate mofetil showed no clear difference in adverse effects: lymphopenia compared with cyclosporin (low certainty).
1 finding from 1 review